Health
Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals – News-Medical.Net
Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021. Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe…
Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021. Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate the safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib.
Opaganib potentially minimizes the likelihood of resistance due to viral mutations by targeting a human cell component involved…
-
Noosa News13 hours agoRevealed: 75 Qld suburbs you could afford to buy in if lending standards drop
-
General24 hours agoTruck driver charged with causing death by dangerous driving after highway crash
-
Noosa News23 hours agoGyrocopter pilot injured in crash-landing on K’Gari, north of Brisbane
-
General9 hours agoChoosing an online exercise program can be confusing. Here’s what to look out for